Life Biosciences, a biotech startup cofounded by Harvard biologist David Sinclair, has raised $80 million in funding to advance its anti-aging gene therapy into clinical trials. The company is developing a one-time treatment designed to reverse cellular aging by rewinding the clock on dying cells.
The funding represents a significant milestone for the longevity research field, which has gained increasing investor attention as companies seek to translate laboratory discoveries into viable therapeutics. Sinclair, a prominent aging researcher at Harvard Medical School, has been a leading advocate for developing interventions that could extend healthy human lifespan.